Expect to See More Biologics Used to Treat Severe Asthma

June 2018

We're getting questions about using omalizumab (Xolair) or other biologics for SEVERE asthma.

These meds reduce inflammation and asthma symptoms by targeting certain mediators...IgE for omalizumab, or interleukin-5 for mepolizumab (Nucala), reslizumab (Cinqair), and benralizumab (Fasenra).

These injectable meds cost between $13,000 and $30,000/year...and are given in a healthcare setting equipped to manage anaphylaxis.

Get concise advice on drug therapy, plus unlimited access to CE

Hospital Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote